XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 151 filers reported holding XENON PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 3.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,496,000 | +88627.3% | 600,000 | 0.0% | 1.09% | +1.9% |
| Q2 2023 | $23,100 | +7.6% | 600,000 | 0.0% | 1.07% | +1.5% |
| Q1 2023 | $21,474 | -99.9% | 600,000 | 0.0% | 1.06% | -15.4% |
| Q4 2022 | $23,658,000 | +9.2% | 600,000 | 0.0% | 1.25% | +2.4% |
| Q3 2022 | $21,660,000 | +18.7% | 600,000 | 0.0% | 1.22% | +5.4% |
| Q2 2022 | $18,252,000 | -0.5% | 600,000 | 0.0% | 1.16% | +22.6% |
| Q1 2022 | $18,342,000 | -2.1% | 600,000 | 0.0% | 0.94% | +29.5% |
| Q4 2021 | $18,744,000 | +43.1% | 600,000 | -30.0% | 0.73% | +59.3% |
| Q3 2021 | $13,095,000 | -17.9% | 857,000 | 0.0% | 0.46% | -18.8% |
| Q2 2021 | $15,957,000 | +140.2% | 857,000 | +42.8% | 0.56% | +144.8% |
| Q3 2020 | $6,642,000 | -11.7% | 600,000 | 0.0% | 0.23% | -30.5% |
| Q2 2020 | $7,524,000 | +10.6% | 600,000 | 0.0% | 0.33% | -28.7% |
| Q1 2020 | $6,804,000 | +71.8% | 600,000 | +100.0% | 0.46% | +5.7% |
| Q3 2018 | $3,960,000 | – | 300,000 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |